IFITM2 and dermatomyositis: In 2018, Shuoshan Xie et al. discovered that IFITM2, LY6E, DDX58, and IFI6 were expressed at higher levels in the muscle tissue of patients with DM, indicating the important role of the interferon (IFN) signaling pathway in the pathogenesis of DM [11].